Vaccination Prior To COVID-19 Infection Provided 60% Protection Against Post-Discharge Mortality: ICMR Research Study

New Delhi : The study on factors related to the post-discharge one-year mortality among hospitalized COVID-19 patients study conducted by the Indian Council of Medical Research (ICMR) has revealed that vaccination prior to the COVID-19 infection (at least a single dose) provided 60 percent protection against post-discharge mortality. The study read,

“The study found a higher chance of dying within one year after discharge in males, those more than 40 years of age, those with comorbidities and those who had moderate-severe COVID disease to begin with. Vaccination prior to the COVID-19 infection (at least a single dose) provided 60% protection against post-discharge mortality. Similar trends were seen in participants, 18-45 years of age.”

It is worth mentioning that these results relate to patients who had been hospitalized during their initial COVID-19 infection and cannot be generalized to all COVID-19 patients.

The study conducted by the National Clinical Registry for Covid-19 team has evaluated the factors related to one-year post-discharge mortality. It said,

“National Clinical Registry for COVID-19 study team has conducted nested matched case-control analyses to evaluate the factors related to one-year post-discharge mortality.”

ICMR has been maintaining the National Clinical Registry for COVID-19 at 31 centres across the country, where all hospitalized COVID-19 patients were periodically contacted by telephone till one year after discharge. Data collected till February 2023 were included in this analysis.

According to the study,

“It was observed that of the 14,419 participants contacted at least once in one year after discharge from hospital, 942 (6.5%) all-cause mortality was reported. A nested matched case-control analysis was conducted to evaluate the factors related to one-year post-discharge mortality.”

ICMR is conducting more such studies like the Effect of the COVID-19 vaccine on thrombotic (blood clot within the blood vessels restricting the flow of blood) events among the 18–45-year-old population in India, 2022, said the Multicentric hospital-based matched case-control study.

Related Posts

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

New Delhi: Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP in…

STF busts fake meds racket spread across 6 states

Dehradun: Uttarakhand special task force (STF) on Friday busted an online fake medicine racket operating through a Facebook page that allegedly sold counterfeit drugs, including cancer medicines, at discounts of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states

All the Way from Teeth to Tee: Hole in One

All the Way from Teeth to Tee: Hole in One

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug